Elicio Therapeutics (Elicio Therapeutics) Net Income : $-38.99 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Elicio Therapeutics's Net Income for the three months ended in Mar. 2024 was $-11.83 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-38.99 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Elicio Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.15.

Elicio Therapeutics Net Income Historical Data

The historical data trend for Elicio Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics Net Income Chart

Elicio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income

-12.26

-15.71

-26.40

-28.21

-35.20

Elicio Therapeutics Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income	Get a 7-Day Free Trial								-8.03	-7.56	-10.66	-8.95	-11.83

Elicio Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Elicio Therapeutics's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-35.195	+	0	+	0	+	0
=	-35.20

Elicio Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as

	Net Income		(Q: Mar. 2024 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-11.827	+	0	+	0	+	0
=	-11.83

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.99 Mil.

Elicio Therapeutics (NAS:ELTX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Elicio Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

Earnings per Share (Diluted) (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-11.827	-	0)	/	10.274
	=	-1.15

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Elicio Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicio Therapeutics (Elicio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

9HA:Germany

Address

One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139

Website

https://www.elicio.com

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Executives

Yekaterina Chudnovsky	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo	director
Peter Demuth	officer: Chief Scientific Officer	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies	officer: Chief Business Officer	ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly	director, officer: CEO, President and Director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams	director	C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq	officer: See Remarks	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos	officer: Chief Financial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022